Your updates for the global forum on pre market medicines access

Share on twitter
Share on facebook
Share on linkedin
Share on email

The Expanded Access Summit is about the smart integration of Expanded Access and Named Patient programs into the modern drug development process.  The annual leadership event was launched in 2017 to establish (and renew) best practices for big pharma, small (pre-revenue) pharma, health care providers, and public and private research networks.  We invite ALL stakeholders to attend.

Our Featured Speakers — So Far

Our track record and leadership in pre-market access allows us to pick top representatives of each stakeholder group for our annual Speaker Faculty.

And, since the Early Bird discount (cutting up to $500 from standard pricing) ends in a few days, we thought we would point out the world-class speakers who are confirmed for this year:

A few of our featured speakers for the 2020 EA3 summit.
  • Janet Woodcock MD, CDER, FDA
  • Marc Boutin, JD, National Health Council
  • Marjorie Speers, PhD, Clinical Research Pathways
  • Frank Young, MD, PhD, Former FDA Commissioner
  • Paul Aliu, PharmD, Novarits Oncology
  • Amy Barone, MD, OCE, FDA
  • Jonathan Darrow, JD, Harvard Medical School
  • Marcel Van Kuijck, PhD, Tricida Pharmaceuticals
  • Alexander Natz, European Pharmaceuticals Federation
  • Erika Segear, PhD, RAC, Duke University Medicine
  • Andrew Schuman, MD, FACS, University of Michigan Medicine
  • Marjorie Speers, PhD, Clinical Research Pathways
  • Kevin Weatherwax, University of Michigan Medicine
  • David Farber, King and Spalding
  • Chris Beardmore, Anova One Source Collaboration
  • Chris Austin, MD, NCATS, National Institutes of Health
  • Suanna Bruinooge, MPH, Director CENTRA, ASCO
  • Tony Fauci, MD, NIAID, National Institutes of Health
  • Michael Kurilla, MD, PhD, NCATS, National Institutes of Health
  • Behtash Bahador, CISCRP
  • Amar Bhat, PhD, The Reagan-Udall Foundation
  • Naomi Bauman Lopez, Goldwater Institute
  • Christina Hartman, MPH, EveryLife Foundation
  • Jeff Leider, X2, “Let Them Be Little” Foundation
  • Peter Pitts, Center for Medicine in the Public Interest
  • Kelly Ranallo, Turner Syndrome Global Alliance
  • Steve Usdin, BioCentury
  • Stuart Bell, PhD, Inceptua
  • Anne Cropp, PharmD, Early Access Care
  • Jess Rabourn, CFA, WideTrial

Here’s what some of our past attendees have said about the Expanded Access Summit:

“Among the many conferences on expanded access, the Expanded Access Summit stood out by focusing on the search for solutions. The discussion brought together the right players – patient advocates, regulators, drug developers — to not only describe barriers to expanded access but also to brainstorm and share strategies for overcoming them. It was a call to action in a high energy, friendly, focused atmosphere.”  
-Elena Gerasimov, Kids v. Cancer

“The Expanded Access Summit provided a platform where attendees could not only get up to speed on changes regarding Expanded Access but could also have an open dialogue. And the food was superb!”
Jennifer Cahill, North Highland

“By far, the best conference on this topic….Excellent speakers, great discussion, fantastic venue, flawless execution.”
-Stuart Bell, PhD, Inceptua Ltd

Registration Details:

Join us in Washington D.C. for the third annual Expanded Access Summit (EA3)!

January 27-29, 2020 at the National Press Club of Washington DC.

Early Bird Registration ends Aug. 9, 2019.

Share on twitter
Share on facebook
Share on linkedin
Share on email